Valentis Licenses Geneswitch Technology To Wyeth-Ayers

Valentis, Inc. has granted a non-exclusive license of the Company’s GeneSwitch gene regulation technology to Wyeth-Ayerst Laboratories. The GeneSwitch system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures, aiding in the identification and characterization of a gene’s function. Valentis is currently developing the GeneSwitch system as Read more about Valentis Licenses Geneswitch Technology To Wyeth-Ayers[…]

Impax Announces Otc Alliance With Wyeth

Impax Laboratories Inc., which has recently won tentative approval from the FDA for a generic version of Claritin tablets, has signed a “semi-exclusive” development, license and supply agreement with Wyeth for this drug. Claritin is marketed by Schering-Plough Corp. for the relief of symptoms of seasonal allergic rhinitis, or hay fever. Worldwide sales of the Read more about Impax Announces Otc Alliance With Wyeth[…]